Form 4: FibroGen CEO Wettig Thane Reports Stock Transaction
SEC Form 4 Filing
CEO Wettig Thane of FibroGen, Inc. reports the disposition of 2,363 shares of common stock to cover tax obligations and an indirect holding of 1,000 shares through a spouse.
Summary
- On September 6, 2024, Thane Wettig, CEO of FibroGen, Inc., reported a transaction involving the company's common stock.
- 2,363 shares were disposed of to satisfy a tax obligation at a price of $0.39.
- Following the transaction, Wettig directly owns 422,316 shares of FibroGen common stock.
- Wettig also indirectly owns 1,000 shares through a spouse.
Sentiment
Score: 5
Explanation: The document is a routine SEC filing reporting a stock transaction. It doesn't inherently convey positive or negative sentiment.
Key Dates
| Date | Description |
|---|---|
| 09/06/2024 | Date of stock transaction |
| 09/09/2024 | Date of signature for the report |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.